GlobeNewswire by notified

CertiK Unveils SkyInsightsTM: A Game-Changer in Crypto Compliance and Risk Management


To view this piece of content from, please give your consent at the top of this page.

Singapore, Sept. 13, 2023 (GLOBE NEWSWIRE) --  CertiK, a leader in Web3 smart contract and blockchain security, today announces the launch of SkyInsightsTM. Designed to address the pressing crypto compliance and risk management demands of Web3 firms and stakeholders, SkyInsightsTM emphasizes CertiK's commitment to raising the standard of security and transparency across the industry. Coming at a time when the global trend of tightening AML/CFT regulations is accelerating, the need for tools like SkyInsights is clearer than ever.

Leveraging CertiK’s extensive and real-time databases, SkyInsightsTM risk insights are enriched with more than two billion wallet address and smart contract labels and over 150 diverse label categories, giving users a comprehensive view of transaction and counterparty risk. Years before terms like DeFi became mainstream, CertiK has been gathering critical data, tagging wallets, identifying security incidents, and providing real-time alerts.

With today’s launch of SkyInsightsTM, this vast reservoir of data is harnessed to redefine the standard of crypto compliance. The platform offers unmatched wallet screening capabilities and the ability to "know your transaction" better than ever. SkyInsightsTM is essential for any business with digital asset exposure that is seeking clarity and control over their transaction and counterparty risks.

The platform seamlessly integrates with CertiK’s comprehensive suite of security services, and further confirms CertiK’s strategy and vision around end-to-end security. Meaningful crypto compliance requires deep insights into all layers of the Web3 stack, from the smart contracts that protocols are built on, to the wallets addresses that interact with them, and finally to the transactions that constitute the on-chain activity that must be monitored. 

SkyInsightsTM comprehensive transaction monitoring software not only flags potential issues but provides actionable insights for swift remediation. Audit trails are automatic, and case escalation is as easy as clicking a button. With SkyInsightsTM, crypto compliance isn't just a regulatory box to be checked, it’s a streamlined process that protects firms with cryptocurrency exposure and reinforces the integrity of the industry. By leveraging CertiK’s advanced security incident monitoring and analysis expertise, along with real-time database updates, SkyInsightsTM ensures alerts are both accurate and on-time.

Jason Cao, Chief Operating Officer at CertiK, states, "The introduction of SkyInsightsTM reaffirms CertiK’s dedication to setting industry benchmarks around security in Web3. With this powerful crypto risk management and compliance tool, we’re not just reacting to the industry's needs but proactively securing the future of Web3."

BitMart, as the first trading platform to adopt CertiK's risk screening and transaction monitoring product SkyInsights, will utilize this collaboration to fully leverage SkyInsights' comprehensive risk and compliance management system to assist users in making wiser decisions.

Furthermore, BitMart and CertiK will work together to advance technology standards for Freeze Asset Requests (FAQ), explore data labeling standards, and standardize information exchange processes, all with the aim of enhancing data accuracy and coverage to promote the security and healthy development of the Web3 industry.

BitMart's Founder and CEO, Sheldon Xia, stated "By integrating the transaction monitoring and real-time alert data provided by SkyInsights, we will offer users more transparent and trustworthy compliance risk control information. We hope that by introducing third-party authoritative security platforms like CertiK, we can further enhance the security of the trading ecosystem and expand BitMart's influence throughout the industry."

Since 2022, CertiK has detected over 1,100 security incidents involving a total loss of $4.8 billion. Leveraging CertiK's extensive database resources, the company’s suite of SaaS security products have been actively monitoring and tracking over two billion wallets and smart contract addresses, providing real-time comprehensive assessments of security trends for nearly 12,000 projects. To date, CertiK has audited over 4,100 Web 3.0 projects, identified nearly 70,000 vulnerabilities in blockchain code, and safeguarded digital assets valued at nearly $370 billion.

SkyInsightsTM is the latest manifestation of CertiK's vision for a more secure, more transparent Web3 world. The platform allows Web3 ventures to concentrate on their core operations, meaning they can build the future of this dynamic industry while resting assured that their compliance needs are met.

About CertiK

CertiK is a pioneer in blockchain security, combining expert manual review with best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK’s mission is to secure the web3 world. CertiK applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.

One of the fastest-growing and most trusted companies in blockchain security, CertiK is a true market leader. To date, CertiK has worked with nearly 4,000 enterprise clients, secured over $360 billion worth of digital assets, and has detected almost 70,000 vulnerabilities in blockchain code. Our clients include leading projects such as Aptos, Ripple, Sandbox, Polygon, BNB Chain, and TON.

​​CertiK is backed by InsightPartners, Sequoia, Tiger Global, Coatue Management, Lightspeed, Advent International, SoftBank, Hillhouse Capital, Goldman Sachs, Coinbase Ventures, Binance, Shunwei Capital, IDG Capital, Wing, Legend Star, Danhua Capital and other investors.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote

Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release

Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla

Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar

EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release

29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the

Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel